Secondary Prevention for Atherosclerotic Cardiovascular Disease-Addressing Gaps in ASCVD Care: SCAI Secondary Prevention Toolkit

Addressing Gaps in ASCVD Care: SCAI Secondary Prevention Toolkit

Video Transcription

Video Summary

The video discusses the 2018 guidelines and individual evidence for non-statin therapy for high-risk patients. It mentions that for patients with established cardiovascular disease but not at high risk, starting high-intensity statin therapy to lower LDL cholesterol by 50% is recommended. For patients over 75 years old already taking statin therapy, continuation of high-intensity or moderate-intensity statin is reasonable. Patients with very high risk should be on high-intensity statin or maximally tolerated statin. The video also discusses follow-up and monitoring of statin therapy, non-statin therapies for statin-intolerant patients, and the use of statins in women of childbearing age. It also mentions the use of ezetimibe, bempedoic acid, and PCSK9 inhibitors as alternative therapies. These therapies have been shown to effectively reduce LDL cholesterol and cardiovascular events in various patient populations.

Asset Subtitle

Debabrata Mukherjee, MD, FSCAI

Keywords

2018 guidelines

non-statin therapy

LDL cholesterol

statin therapy

cardiovascular events